Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other financing activities (2020 - 2025)

Historic Other financing activities for Ligand Pharmaceuticals (LGND) over the last 5 years, with Q3 2025 value amounting to $14.8 million.

  • Ligand Pharmaceuticals' Other financing activities rose 696571.43% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 109562.45%. This contributed to the annual value of $426000.0 for FY2024, which is 5511.06% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Other financing activities stood at $14.8 million for Q3 2025, which was up 696571.43% from $2000.0 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Other financing activities peaked at $14.8 million during Q3 2025, and registered a low of -$121000.0 during Q1 2022.
  • For the 4-year period, Ligand Pharmaceuticals' Other financing activities averaged around $1.4 million, with its median value being $64000.0 (2024).
  • The largest annual percentage gain for Ligand Pharmaceuticals' Other financing activities in the last 5 years was 696571.43% (2025), contrasted with its biggest fall of 9649.12% (2025).
  • Ligand Pharmaceuticals' Other financing activities (Quarter) stood at $42000.0 in 2022, then surged by 2159.52% to $949000.0 in 2023, then tumbled by 87.57% to $118000.0 in 2024, then skyrocketed by 12474.58% to $14.8 million in 2025.
  • Its Other financing activities stands at $14.8 million for Q3 2025, versus $2000.0 for Q2 2025 and $71000.0 for Q1 2025.